These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 29937245)

  • 1. Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016.
    Demczuk WHB; Martin I; Desai S; Griffith A; Caron-Poulin L; Lefebvre B; McGeer A; Tyrrell GJ; Zhanel GG; Gubbay J; Hoang L; Levett PN; Van Caeseele P; Raafat Gad R; Haldane D; Zahariadis G; German G; Daley Bernier J; Strudwick L; Mulvey MR
    Vaccine; 2018 Jul; 36(31):4701-4707. PubMed ID: 29937245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.
    Demczuk WH; Martin I; Griffith A; Lefebvre B; McGeer A; Lovgren M; Tyrrell GJ; Desai S; Sherrard L; Adam H; Gilmour M; Zhanel GG; ;
    Can J Microbiol; 2013 Dec; 59(12):778-88. PubMed ID: 24313450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
    Ciruela P; Izquierdo C; Broner S; Muñoz-Almagro C; Hernández S; Ardanuy C; Pallarés R; Domínguez A; Jané M;
    Vaccine; 2018 Nov; 36(50):7744-7752. PubMed ID: 30473132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.
    Shigayeva A; Rudnick W; Green K; Chen DK; Demczuk W; Gold WL; Johnstone J; Kitai I; Krajden S; Lovinsky R; Muller M; Powis J; Rau N; Walmsley S; Tyrrell G; Bitnun A; McGeer A;
    Clin Infect Dis; 2016 Jan; 62(2):139-47. PubMed ID: 26354970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
    Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
    Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
    Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.
    Hsu KK; Shea KM; Stevenson AE; Pelton SI;
    Pediatr Infect Dis J; 2010 Apr; 29(4):289-93. PubMed ID: 19935447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
    Kendall BA; Dascomb KK; Mehta RR; Stockmann C; Mason EO; Ampofo K; Pavia AT; Byington CL
    Vaccine; 2016 Jan; 34(4):474-478. PubMed ID: 26706276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.
    van der Linden M; Falkenhorst G; Perniciaro S; Imöhl M
    PLoS One; 2015; 10(7):e0131494. PubMed ID: 26132078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children.
    Hays C; Vermee Q; Agathine A; Dupuis A; Varon E; Poyart C; Ploy MC; Raymond J;
    Eur J Clin Microbiol Infect Dis; 2017 May; 36(5):831-838. PubMed ID: 28000028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany.
    Imöhl M; Reinert RR; van der Linden M
    Int J Med Microbiol; 2015 Oct; 305(7):776-83. PubMed ID: 26324014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
    Shibl AM; Memish ZA; Al-Kattan KM
    Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
    Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B
    Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005.
    Messina AF; Katz-Gaynor K; Barton T; Ahmad N; Ghaffar F; Rasko D; McCracken GH
    Pediatr Infect Dis J; 2007 Jun; 26(6):461-7. PubMed ID: 17529859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
    Wijayasri S; Hillier K; Lim GH; Harris TM; Wilson SE; Deeks SL
    PLoS One; 2019; 14(12):e0226353. PubMed ID: 31834926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.